Signatera MRD Testing for NSCLC Patient Management

Personalized ctDNA testing in Urothelial Cancer

New data. Better insight. The future of precision breast cancer management

An MRD-guided approach to advancing treatment strategies in gynecologic cancer

Shaping the future of skin cancer: Tumor-informed ctDNA-guided interventions

From Detection to Decision-Making: Utility of Signatera in Complex GI & Hepatobiliary Malignancies

Integrating ctDNA and utDNA Across the Bladder Cancer Continuum

From Detection to Direction: Signatera MRD testing and its impact in CRC

Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development

Optimizing Breast Cancer Surveillance: A team approach with MRD testing

Leadership at Diagnosis: Quarterbacking the Path to Precision Care

Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing

New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

Tiny Traces, Big Impact: Changing the Paradigm in Breast Cancer Management with MRD Testing

Optimizing Patient Care in MIBC with MRD Testing, Real-world Clinical Cases

New Data Review Can treating molecular residual disease (MRD) in colorectal cancer improve outcomes

MRD Testing in NSCLC to Personalize Patient Care

Unlocking new uses for old drugs

a revolution in precision oncology using evidence-based MRD testing